Iron Overload
Information
- Disease name
- Iron Overload
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes | Mutation | Description | Source | Links |
---|
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT00907283 | Active, not recruiting | Phase 2 | Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA) | November 2008 | December 2024 |
NCT04198545 | Active, not recruiting | Ethnic Differences in Iron Absorption (FeGenes) | August 1, 2019 | March 31, 2025 | |
NCT00293098 | Approved for marketing | Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease | March 2006 | ||
NCT00001455 | Completed | Iron Overload in African Americans | June 1995 | June 2000 | |
NCT00004982 | Completed | Phase 1 | Combination Iron Chelation Therapy | December 1998 | November 2002 |
NCT00005541 | Completed | Hemochromatosis and Iron Overload Screening Study (HEIRS) | January 2000 | January 2006 | |
NCT00110266 | Completed | Phase 2 | Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients | July 25, 2005 | March 28, 2008 |
NCT00110617 | Completed | Phase 2 | Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients | May 2005 | April 2008 |
NCT00117507 | Completed | Phase 4 | Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients | September 2005 | January 2008 |
NCT00138684 | Completed | Phase 2 | Cytochrome P450 2E1 and Iron Overload | September 2003 | February 2006 |
NCT00171301 | Completed | Phase 4 | Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) | June 2005 | May 2008 |
NCT00395629 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis | August 2006 | March 2009 |
NCT00401336 | Completed | N/A | Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging | November 2006 | March 2013 |
NCT00447694 | Completed | Phase 2 | Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment | February 2006 | November 2009 |
NCT00512226 | Completed | N/A | Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia | September 2007 | December 2010 |
NCT00529152 | Completed | Phase 3 | Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients | August 2007 | July 2008 |
NCT00629291 | Completed | MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfusions. | January 2008 | May 2010 | |
NCT00000588 | Completed | Phase 2 | Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone | June 5, 1989 | March 31, 1995 |
NCT00689182 | Completed | Phase 2 | Safety and Efficacy of Iron Reduction by Phlebotomy | May 2007 | December 2012 |
NCT00712738 | Completed | Phase 1 | Oral Nifedipine to Treat Iron Overload | June 20, 2008 | September 22, 2010 |
NCT00800761 | Completed | Phase 4 | Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major | December 2001 | June 2006 |
NCT00806715 | Completed | Iron Overload in Stem Cell Transplant Recipients | February 2007 | October 2010 | |
NCT00901199 | Completed | Phase 2 | Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload | September 2007 | October 2012 |
NCT00654589 | Completed | Phase 4 | Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload | February 2008 | January 2012 |
NCT00000595 | Completed | Phase 2 | Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis | January 1978 | September 1994 |
NCT00000623 | Completed | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) | July 2000 | July 2006 | |
NCT01034072 | Completed | Iron Overload in Pediatric Oncology Patients | December 2009 | January 2012 | |
NCT01045525 | Completed | Phase 3 | Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic Liversiderosis | January 2010 | December 2015 |
NCT01047098 | Completed | N/A | Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation | October 2008 | April 2010 |
NCT01335035 | Completed | Phase 4 | Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload | December 2008 | |
NCT01369719 | Completed | N/A | Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload | February 2010 | May 2011 |
NCT01376622 | Completed | Changes in Pituitary Iron and Volume With Deferasirox | November 2008 | July 1, 2011 | |
NCT01395199 | Completed | Phase 3 | Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major | August 2012 | February 2015 |
NCT01516853 | Completed | Non-invasive Quantification of Liver Iron With MRI | January 2012 | June 2015 | |
NCT01546415 | Completed | Phase 4 | Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia | October 2011 | November 2013 |
NCT01572818 | Completed | N/A | Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients | October 2010 | October 2015 |
NCT01572922 | Completed | N/A | Massive Iron Deposit Assessment | June 11, 2012 | February 28, 2018 |
NCT01874405 | Completed | Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy | March 2003 | October 2012 | |
NCT01905774 | Completed | Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox | March 2011 | August 2015 | |
NCT02155114 | Completed | Iron Homoeostasis in Inflammation | April 2014 | ||
NCT02164253 | Completed | Phase 2 | Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients | September 2013 | December 2016 |
NCT02425956 | Completed | N/A | Non-invasive Quantification of Liver Iron With MRI | April 2015 | June 30, 2016 |
NCT02527330 | Completed | Evaluation of Myocardial Iron Deposition in Patients of Heart Failure Using T2* MR Imaging | January 2014 | December 2016 | |
NCT02880033 | Completed | N/A | Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes | February 2011 | March 2020 |
NCT03372083 | Completed | Phase 4 | Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis | January 16, 2018 | December 5, 2019 |
NCT03591575 | Completed | Phase 4 | Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children | November 9, 2018 | September 29, 2020 |
NCT03990181 | Completed | N/A | Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement | September 20, 2019 | August 15, 2020 |
NCT04018300 | Completed | N/A | Iron Supplementation and Side Effects | January 8, 2018 | April 18, 2018 |
NCT04292314 | Completed | Phase 2/Phase 3 | Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia | November 1, 2019 | January 20, 2021 |
NCT04515680 | Completed | Endocrine Function During Deferasirox Therapy | November 2, 2016 | January 30, 2019 | |
NCT04614779 | Completed | Phase 2 | Long-term Clinical Study of CN128 in Thalassemia Patients | September 30, 2020 | August 18, 2022 |
NCT04631718 | Completed | MRI QSM Imaging for Iron Overload | January 18, 2022 | April 29, 2024 | |
NCT02025543 | Enrolling by invitation | Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content | August 12, 2015 | September 2024 | |
NCT05294471 | Recruiting | Fully Automated High-Throughput Quantitative MRI of the Liver | October 16, 2023 | September 2026 | |
NCT06146608 | Recruiting | Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption | January 15, 2023 | January 14, 2026 | |
NCT04423237 | Recruiting | Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT | September 30, 2020 | December 31, 2024 | |
NCT05355766 | Recruiting | Phase 2 | Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients | June 2, 2022 | December 31, 2024 |
NCT06137079 | Recruiting | "Iron Overload and Endocrinological Diseases" | June 20, 2013 | December 31, 2025 | |
NCT04741542 | Suspended | Phase 1 | Safety of SP-420 in the Treatment of Transfusional Iron Overload | March 9, 2021 | August 2025 |
NCT00602446 | Terminated | Phase 2 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | August 2007 | December 2009 |
NCT03777904 | Terminated | The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin Levels | February 21, 2019 | December 10, 2019 | |
NCT02041299 | Terminated | Phase 4 | Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias | April 17, 2014 | June 18, 2019 |
NCT02274233 | Terminated | Phase 1 | Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia | October 2014 | September 2015 |
NCT01159067 | Terminated | Phase 2 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | July 2010 | August 9, 2011 |
NCT02443545 | Terminated | Phase 4 | Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias | May 21, 2015 | August 21, 2019 |
NCT01342705 | Terminated | Phase 3 | Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis | May 2011 | June 2014 |
NCT05326503 | Unknown status | N/A | Inhibitory Effect of a Polyphenol Supplement on Dietary Iron Absorption in Adults With Thalassemia | May 1, 2022 | December 31, 2022 |
NCT00980421 | Unknown status | Phase 3 | Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children | October 2009 | August 2010 |
NCT00999349 | Unknown status | Phase 2/Phase 3 | Therapeutic Effects of Silymarin in Patients With B-thalassemia Major | March 2009 | |
NCT02474420 | Unknown status | N/A | Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients | June 2015 | June 2018 |
NCT01121094 | Unknown status | Fetal Parenchymatic Evaluation (Liver, Spleen) Using T2* Sequences | June 2010 | June 2012 | |
NCT01169961 | Unknown status | Assessment of Iron Deposition in Major Organs of Hemodialysis Patients | February 2010 | August 2010 | |
NCT02833493 | Unknown status | Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload | September 2016 | October 2019 | |
NCT01443195 | Unknown status | N/A | Iron Metabolism in Small Pre Term Newborns | October 2011 | December 31, 2020 |
NCT04835285 | Unknown status | N/A | MRI T2* Mapping of Myocardium, Liver, Pancreas and Pituitary Gland | January 21, 2020 | January 21, 2023 |
NCT00378469 | Unknown status | N/A | Study of the Effects of Muscular Activity on Iron Metabolism | September 2006 | |
NCT03801889 | Withdrawn | Phase 2 | SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias | August 2020 | January 2023 |
NCT03800446 | Withdrawn | N/A | Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood | September 2019 | June 2020 |
NCT03141398 | Withdrawn | Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group | August 2017 | December 2018 | |
NCT01927913 | Withdrawn | Phase 2 | Treatment of Iron Overload Requiring Chelation Therapy | November 20, 2014 | October 30, 2015 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D019190